{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:48:35Z","timestamp":1789724915094,"version":"4.0.1"},"reference-count":55,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T00:00:00Z","timestamp":1238025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p>\n                    <jats:bold>Background and purpose:\u2002<\/jats:bold>\n                    As a combination of 5\u2010HT selective reuptake inhibitor (SSRI) with 5\u2010HT\n                    <jats:sub>1A<\/jats:sub>\n                    receptor antagonism may yield a rapidly acting antidepressant, WAY\u2010211612, a compound with both SSRI and 5\u2010HT\n                    <jats:sub>1A<\/jats:sub>\n                    receptor antagonist activities, was evaluated in preclinical models.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Experimental approach:\u2002<\/jats:bold>\n                    Occupancy studies confirmed the mechanism of action of WAY\u2010211612, while its\n                    <jats:italic>in vivo<\/jats:italic>\n                    profile was characterized in microdialysis and behavioural models.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Key results:\u2002<\/jats:bold>\n                    WAY\u2010211612 inhibited 5\u2010HT reuptake (K\n                    <jats:sub>i<\/jats:sub>\n                    \u2003=\u20031.5\u2003nmol\u00b7L\n                    <jats:sup>\u22121<\/jats:sup>\n                    ; K\n                    <jats:sub>B<\/jats:sub>\n                    \u2003=\u200317.7\u2003nmol\u00b7L\n                    <jats:sup>\u22121<\/jats:sup>\n                    ) and exhibited full 5\u2010HT\n                    <jats:sub>1A<\/jats:sub>\n                    receptor antagonist activity (K\n                    <jats:sub>i<\/jats:sub>\n                    \u2003=\u20031.2\u2003nmol\u00b7L\n                    <jats:sup>\u22121<\/jats:sup>\n                    ; K\n                    <jats:sub>B<\/jats:sub>\n                    \u2003=\u20036.3\u2003nmol\u00b7L\n                    <jats:sup>\u22121<\/jats:sup>\n                    ; I\n                    <jats:sub>max<\/jats:sub>\n                    100% in adenyl cyclase assays; K\n                    <jats:sub>B<\/jats:sub>\n                    \u2003=\u200319.8\u2003nmol\u00b7L\n                    <jats:sup>\u22121<\/jats:sup>\n                    ; I\n                    <jats:sub>max<\/jats:sub>\n                    100% in GTP\u03b3S). WAY\u2010211612 (3 and 30\u2003mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , po) occupied 5\u2010HT reuptake sites in rat prefrontal cortex (56.6% and 73.6% respectively) and hippocampus (52.2% and 78.5%), and 5\u2010HT\n                    <jats:sub>1A<\/jats:sub>\n                    receptors in the prefrontal cortex (6.7% and 44.7%), hippocampus (8.3% and 48.6%) and dorsal raphe (15% and 83%). Acute or chronic treatment with WAY\u2010211612 (3\u201330\u2003mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , po) raised levels of cortical 5\u2010HT approximately twofold, as also observed with a combination of an SSRI (fluoxetine; 30\u2003mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , s.c.) and a 5\u2010HT\n                    <jats:sub>1A<\/jats:sub>\n                    antagonist (WAY\u2010100635; 0.3\u2003mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , s.c). WAY\u2010211612 (3.3\u201330\u2003mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , s.c.) decreased aggressive behaviour in the resident\u2010intruder model, while increasing the number of punished crossings (3\u201330\u2003mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , i.p. and 10\u201356\u2003mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , po) in the mouse four\u2010plate model and decreased adjunctive drinking behaviour (56\u2003mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , i.p.) in the rat scheduled\u2010induced polydipsia model.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions and implications:\u2002<\/jats:bold>\n                    These findings suggest that WAY\u2010211612 may represent a novel antidepressant.\n                  <\/jats:p>","DOI":"10.1111\/j.1476-5381.2009.00146.x","type":"journal-article","created":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T11:44:03Z","timestamp":1238067843000},"page":"307-319","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Preclinical characterization of WAY\u2010211612: a dual 5\u2010HT uptake inhibitor and 5\u2010HT\n                    <sub>1A<\/sub>\n                    receptor antagonist and potential novel antidepressant"],"prefix":"10.1111","volume":"157","author":[{"given":"CE","family":"Beyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Malberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hornby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KM","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DL","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PJ","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NT","family":"Hatzenbuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DA","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BL","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Magolda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MN","family":"Pangalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LE","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Rosenzweig\u2010Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TH","family":"Andree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03398-2"},{"issue":"2","key":"e_1_2_7_3_1","first-page":"S1","article-title":"Guide to receptors and channels (GRAC), 3rd edition (2008 revision)","volume":"153","author":"Alexander SPH","year":"2008","journal-title":"Br J Pharmacol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00592-0"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950030084009"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(96)10037-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945006775515446"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00404-4"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.1.37"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.11.028"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600403"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199506000-00011"},{"issue":"5","key":"e_1_2_7_13_1","first-page":"16","article-title":"The use of pindolol to potentiate antidepressant medication","volume":"59","author":"Blier P","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(94)90315-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00500007"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(93)90181-2"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(96)00391-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01580-X"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(94)90071-X"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703496"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.12.064"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb15919.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702546"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00565-4"},{"issue":"6","key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1017\/S1092852900025463","article-title":"Making advances where it matters: improving outcomes in mood and anxiety disorders","volume":"9","author":"Golden RN","year":"2004","journal-title":"CNS Spectr"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(99)00191-4"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060218h"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00175-5"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(97)00050-6"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2003.09.020"},{"key":"e_1_2_7_32_1","first-page":"6P","article-title":"Evidence that pindolol lacks the ability to enhance the effect of SSRIs on presynaptic 5\u2010HT function","volume":"125","author":"Hughes ZA","year":"1998","journal-title":"Br J Pharmacol"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.01.018"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(92)90914-U"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(95)02159-0"},{"key":"e_1_2_7_36_1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0022-3565(25)10650-2","article-title":"Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5\u2010hydroxytryptamine measured in vivo","volume":"274","author":"Kreiss DS","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13738.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301358"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0304010"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.11.006"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.09.029"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-199711000-00016"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.283.5400.401"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(90)90520-J"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.29.17189"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0293-z"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.02.088"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.68062593.x"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.2.4.590"},{"key":"e_1_2_7_50_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)09485-6","article-title":"DOI\u2010induced Head\u2010Twitches in the rat are mediated by 5\u2010HT2A receptors: modulation by novel 5\u2010HT2A\/C receptor antagonists, D1 antagonists and 5\u2010HT1A agonists","volume":"273","author":"Schreiber R","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701235"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000466"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2007.00012.x"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357021017"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244910"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(01)00079-1"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2009.00146.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2009.00146.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T13:04:29Z","timestamp":1739019869000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2009.00146.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,28]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1476-5381.2009.00146.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00146.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,28]]},"assertion":[{"value":"2009-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}